Pharma Business - June 1, 2020
Jan Lundberg invests in Sigrid Therapeutics
Sigrid Therapeutics has announced that pharmaceutical R&D leader, Dr. Jan Lundberg has joined the company as an investor and member of the Scientific Advisory Board. Jan Lundberg has more than 20 years of leadership experience from executive positions in the global pharmaceutical companies AstraZeneca (1996-2009) and Eli Lilly (2010-2018). He has overseen the development of […]
MedTech Business - May 5, 2020
New study provides proof of concept for Sigrid’s medical device
Sigrid Therapeutics has announced the publication of a multifaceted, scientific study in the peer-reviewed journal Advanced Healthcare Materials showing that a new approach using mesoporous silica particles (MSPs) can be used to prevent type 2-diabetes and treat obesity. By blocking food enzyme activity, MSPs reduce energy intake from food and lower blood sugar and other […]
Financing - March 26, 2020
The Stockholm Material Hub receives 0.5 MEUR from European Regional Development Fund
The Stockholm Material Hub (SMH) has secured funding from the EU’s European Regional Development Fund, enabling continued research into novel materials and their use in life science applications. SMH is coordinated by Stockholm University (SU) and integrates materials expertise existing in Royal Institute of Technology (KTH), Karolinska Institute (KI) and other academic institutions. The vision […]
Drug Development Pharma - January 16, 2020
New study shows Sigrid’s medical device prevents weight gain
Sigrid Therapeutics has announced the publication of a study in mice in the journal Nanomedicine demonstrating the enzyme-blocking effects of mesoporous silica particles (MSPs) introduced to the gut and the resulting effect on food efficiency and metabolic risk factors. “These results are very exciting and open up for new possibilities of SiPore15 to be used […]
Clinical Trials - September 26, 2019
Sigrid Therapeutics reports new results from their Proof of Concept STAR study
The company has reported the first results from their Proof of Concept STAR study in subjects with prediabetes or newly diagnosed type 2 diabetes. The company’s lead product, SiPore15, an orally administered non-absorbed medical device, demonstrated a 1,4 mmol/mol mean reduction in HbA1c, a key marker of glucose control (p=0.0391). SiPore15 showed no increased safety […]
MedTech Award - August 16, 2019
Swedish companies nominated for “Medtech Oscars”
Elypta, Pilloxa and Sigrid Therapeutics have been announced as finalists in this year’s Medtech Insight Awards, an award that celebrates and recognizes excellence among the companies, teams, and individuals driving positive change across the global medtech industry. Ten distinct categories cover notable achievements across the device and diagnostics industries, from technological innovations and partnerships, to […]
